Boston Hemophilia Center
Hemophilia is a lifelong disease, but significant advances in preventing bleeding episodes and better treatment means that those with hemophilia suffer fewer damaging consequences of the illness than ever before. Innovations in the production of synthetic factor products have also enhanced safety and reduced complications.
The Boston Hemophilia Center is dedicated to advancing understanding and treatment of hemophilia. Our investigators participate in large, multi-center research studies, and also lead smaller independent initiatives to help improve treatment.
We currently offer several active clinical research studies for bleeding disorders. These studies are available to children with hemophilia A, hemophilia B, hemophilia with inhibitors and Von Willebrand disease, as well as women with bleeding disorders and factor XIII deficiency.
- We are also conducting research that we hope will help to improve the lifestyle of our patients, including trials of new, longer-acting replacement factors aimed at reducing the frequency of required treatment. In addition, we are investigating the possible use of gene therapy to treat hemophilia and other bleeding disorders.
For more information about our research, please contact research coordinator Latoya Lashley at 617-355-8733 or via email.